Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of triple-negative breast cancer cells by Nitidine Chloride(NCD)

ABSTRACT: To obtain the gene expression profiles of triple-negative breast cancer MDA-MB-231 cells perturbed by NCD, we treated MDA-MB-231 with either DMSO or 5 μM NCD for 24 hours. By comparing the expression profiles of DMSO-treated cells with those treated with Nitidine Chloride, we can identify the genes affected by Nitidine Chloride.

ORGANISM(S): Homo sapiens

PROVIDER: GSE294840 | GEO | 2025/12/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Proteomics of Triple Negative Breast Cancer Cells Treated with SU056

Project description:1. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and MCF12A cells were treated with DMSO (vehicle control) or SU056 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates. 2. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the resulting soluble and insoluble fractions were determined.3. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 YBOX1 KD cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the soluble fractions were determined.

2024-04-04 | PXD042380 | Pride

Gene expression profiling of triple-negative breast cancer cells by Nitidine Chloride(NCD)

Project description:Gene expression profiling of triple-negative breast cancer cells by Nitidine Chloride(NCD)

| PRJNA1251674 | ENA

Non-allosteric Inhibition of Enolase 1 Impedes Growth of Triple-Negative Breast Cancer

Project description:1. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated for 6h with DMSO or SU212 and incubated at different temperatures and protein differences in the soluble fractions were determined. 2. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and BT549 cells were treated with DMSO (vehicle control) or SU212 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates.

2025-10-10 | PXD061466 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h.Sample IDs:#1-5 Control 30 min DLD-1#6-10 FT671 30 min DLD-1#11-15 WEHI-092 30 min DLD-1#16-20 Control 360 min DLD-1#21-25 FT671 360 min DLD-1#26-30 WEHI-092 360min DLD-1#31-35 Control 30 min MDA-MB-231#36-40 WEHI-092 30 min MDA-MB-231#41-45 Control 360 min MDA-MB-231#46-50 WEHI-092 360 min MDA-MB-231#51-55 Control 24 h MDA-MB-231#56-60 WEHI-092 24 h MDA-MB-231

2026-04-09 | PXD073869 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:Global proteomics dataset for K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231

2026-04-09 | PXD074673 | Pride

Global analysis of cancer cell responses to USP9X inhibition

Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231

2026-04-09 | PXD075275 | Pride

Gene expression profiling of triple-negative breast cancer cells and liver cancer cells perturbed by BET inhibitor JQ1

Project description:To obtain the gene expression profiles of triple-negative breast cancer MDA-MB-231 cells and liver cancer HepG2 cells perturbed by the BET inhibitor JQ1, we treated MDA-MB-231 and HepG2 cells with either DMSO (control) or 10 μM JQ1 for 24 hours. By comparing the expression profiles of DMSO-treated cells with those treated with JQ1, we can identify the genes affected by JQ1.

2025-08-22 | GSE294293 | GEO

Global analysis of cancer cell responses to USP9X inhibition

Project description:Treatment of cancer cells MDA-MB-231 and MiaPaca2 with WEHI-092 (10 uM, 24 h) or FT709 (10 uM, 24 h). Sample key of raw file in ZIP folder: #1-6 MDA-MB-231 DMSO (untreated); #13-18 MDA-MB-231 FT709; #19-24 MDA-MB-231 WEHI-092; #25-30 MiaPaca2 DMSO (untreated); #37-42 MiaPaca2 FT709; #43-48 MiaPaca2 WEHI-092.

2026-04-09 | PXD074729 | Pride

Roscovitinen suppresses TRIM32 nuclear translocaton via STAT3 signaling

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of MDA-MB-231 cells treated with Roscovitinen and DMSO

2024-07-25 | GSE210030 | GEO

Effect of Nitidine Chloride on Rheumatoid Synovial Fibroblast-like Synoviocytes

Project description:To explore how nitidine chloride (NC) regulates biological functions of fibroblast-like synovioctyes (FLSs) from rheumatoid arthritis (RA) patients, we evaluated the transcriptome of NC-treated RA FLSs compared with untreated control using RNA sequencing analysis.

2021-10-06 | GSE185040 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data